Stockpolly
Search
PYXS · NASDAQ · Biotechnology

Pyxis Oncology (PYXS)

Develops MICVO, an investigational ADC for difficult-to-treat solid tumors.

$3.73
Pre-market−0.01 (−0.27%)
At close$3.74(+8.72%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue00160000301100
Cost of revenue000000000000
Gross profit00160000301100
251821202440232323302426
Research & development151213141814171718222016
11686656555410
Selling & marketing00000000−1000
General & administrative11686656565410
Other expenses0000021001300
Operating income−25−18−6−20−24−40−23−20−23−18−24−26
222332221111
Interest income222222111100
Other non-operating income0−2−2−3−3−21−2−2−1−1−1−1
Income before tax−23−16−3−17−21−38−21−18−22−17−23−25
Income tax expense00000−2000100
Net income from continuing operations−23−16−3−17−21−36−21−18−22−18−23−25
Net income−23−16−3−17−21−36−21−18−22−18−23−25
EPS, basic−$0.56−$0.35−$0.06−$0.29−$0.35−$0.58−$0.35−$0.30−$0.35−$0.29−$0.37−$0.40
EPS, diluted−$0.56−$0.35−$0.06−$0.29−$0.35−$0.58−$0.35−$0.30−$0.35−$0.29−$0.37−$0.40
Weighted average shares, basic414551606161616263626364
Weighted average shares, diluted414551606161616263626364
EBITDA−25−15−2−17−20−19−21−18−21−14−23−25
Depreciation & amortization111111111300
EBIT−25−16−3−17−21−19−21−18−22−17−23−25